Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.58 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.58 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.58 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.48 |
| ▸ | METAP2 | P50579 | 1/20 | 0.48 |
| ▸ | APEX1 | P27695 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2209568 | 0.88 | KCNA5 (0.57) | LMNAPOLBALDH1A1KCNA5HDAC4 | |
| SCHEMBL2209222 | 0.81 | KMT2A (0.51) | HPGDL3MBTL1KMT2AALDH1A1MEN1 | |
| SCHEMBL2210817 | 0.80 | CHRNB2 (0.66) | CHRNB2CHRNA4CHRNB4CHRNA3GAA | |
| SCHEMBL2207285 | 0.79 | KCNA5 (0.66) | LMNAKMT2AMAPK1KCNA5 | |
| SCHEMBL5697875 | 0.79 | POLB (0.50) | GAAPOLBKMT2AALDH1A1MEN1 | |
| SCHEMBL7828799 | 0.77 | KMT2A (0.77) | CHRNB2CHRNA4CHRNB4CHRNA3GAA | |
| SCHEMBL2211346 | 0.76 | KCNA5 (0.70) | CHRNB2CHRNA4CHRNB4CHRNA3GAA | |
| SCHEMBL2211351 | 0.76 | KCNA5 (0.62) | LMNAPOLBKMT2AALDH1A1MEN1 | |
| SCHEMBL1251436 | 0.74 | KMT2A (0.56) | HPGDKMT2AALDH1A1MEN1HDAC1 | |
| SCHEMBL31751956 | 0.74 | KMT2A (0.56) | HPGDKMT2AALDH1A1MEN1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7982045-B2 | 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-07-19 | — | — | US | disclosed |
| US-20090192096-A1 | 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-07-30 | — | — | US | disclosed |
| US-7514582-B2 | 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-04-07 | — | — | US | disclosed |
| US-20040102513-A1 | 2'-Substituted 1,1'-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2004-05-27 | — | — | US | disclosed |
| US-6686395-B2 | THERAPY OF A CARDIAC ARRYTHMIA WHICH CAN BE ELIMINATED BY ACTION POTENTIAL PROLONGATION; POTASSIUM CHANNEL MODULATOR | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-03 | — | — | US | disclosed |
| US-20030171351-A1 | 2'-substituted 1,1'-biphenyl-2-carboxamides, process for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-09-11 | — | — | US | disclosed |
| US-6531495-B1 | Potassium channel | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171351-A1 | 2'-substituted 1,1'-biphenyl-2-carboxamides, process for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | MLLT3, RYR2, KCNH1 | CHRNB2 1479/4885CHRNA4 963/4885CHRNB4 1599/4885 |
| US-20090192096-A1 | 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them | MLLT3, RYR2, CACNA1E | CHRNB2 1297/4885CHRNA4 834/4885CHRNB4 1424/4885 |
| US-20040102513-A1 | 2'-Substituted 1,1'-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | MLLT3, RYR2, CACNA1E | CHRNB2 1535/4885CHRNA4 1003/4885CHRNB4 1671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.